Patents by Inventor Tomihisa Yokoyama
Tomihisa Yokoyama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210052537Abstract: To provide a novel colitis ameliorating agent. A colitis ameliorating agent comprising a trans-astaxanthin derivative of formula (I), geometric isomers thereof, a mixture of the geometric isomers, an optical isomer thereof, or a salt thereof; (wherein m1, m2, n1, and n2 are each the same or different and mean an integer of 1 to 6).Type: ApplicationFiled: February 12, 2019Publication date: February 25, 2021Applicant: ASTA PHARMACEUTICALS, CO., LTD.Inventors: Michinori TAKASHINA, Makoto OGAWA, Kaoru KOBAYASHI, Yasuhiro NISHIDA, Akiko NAKAGAWA, Takashi FUJITA, Satoshi KOBAYASHI, Ryoma SHINOHARA, Yuji IWANO, Kiyotaka MORIIZUMI, Sachi MAEDA, Ryo SAKATA, Tomihisa YOKOYAMA
-
Publication number: 20080221184Abstract: A pharmaceutical composition for the treatment of glaucoma which comprises an angiotensin II antagonist and a prostaglandin which is unoprostone or latanoprost, and a method for treatment of glaucoma by administering the composition to a patient.Type: ApplicationFiled: October 23, 2007Publication date: September 11, 2008Applicant: SANKYO COMPANY LIMITEDInventor: Tomihisa Yokoyama
-
Patent number: 7307096Abstract: A pharmaceutical composition for the prophylaxis or treatment of glaucoma which comprises an angiotensin II antagonist and at least one compound selected from an adrenaline receptor blocker, a prostaglandin and a carbonic anhydrase inhibitor; and a method for the prophylaxis or treatment of glaucoma by administering the composition to a patient.Type: GrantFiled: May 16, 2002Date of Patent: December 11, 2007Assignee: Sankyo Company, LimitedInventor: Tomihisa Yokoyama
-
Publication number: 20070203211Abstract: A method for the prevention or treatment of intraocular angiogenic diseases such as proliferative retinopathy, retinal vein occlusion, retinal artery occlusion or age-related macular degeneration, which comprises administering to a mammal (such as a human) in need thereof a pharmaceutically effective amount of an angiotensin II receptor antagonist such as 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[2?-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]imidazole-5-carboxylic acid.Type: ApplicationFiled: October 4, 2005Publication date: August 30, 2007Applicant: SANKYO COMPANY, LIMITEDInventors: Tomihisa Yokoyama, Tatsuya Inoue
-
Publication number: 20050043383Abstract: A pharmaceutical composition for the prophylaxis or treatment of glaucoma which comprises an angiotensin II antagonist and timolol maleate and a method for the prophylaxis or treatment of glaucoma by administering the composition to a patient.Type: ApplicationFiled: August 10, 2004Publication date: February 24, 2005Applicant: SANKYO COMPANY, LIMITEDInventor: Tomihisa Yokoyama
-
Publication number: 20050014808Abstract: A pharmaceutical composition for the prophylaxis or treatment of glaucoma which comprises an angiotensin II antagonist and dorzolamide or a pharmacologically acceptable salt thereof, and a method for the prophylaxis or treatment of glaucoma by administering the composition to a patient.Type: ApplicationFiled: August 10, 2004Publication date: January 20, 2005Applicant: SANKYO COMPANY, LIMITEDInventor: Tomihisa Yokoyama
-
Patent number: 6777436Abstract: An intraocular tension lowering composition for topical administration is disclosed which comprises an effective amount of an (i) angiotensin II antagonist, (ii) a boric aid and (iii) an ethylenediamine tetraacetic acid. Said composition has excellent intraocular tension lowering activity. Said composition may be effectively administered to humans and other warm-blooded animals to lower intraocular tension.Type: GrantFiled: December 10, 2001Date of Patent: August 17, 2004Assignee: Sankyo Company, LimitedInventors: Tomihisa Yokoyama, Takashi Shiokari
-
Publication number: 20030040529Abstract: A pharmaceutical composition for the prophylaxis or treatment of glaucoma which comprises an angiotensin II antagonist and at least one compound selected from an adrenaline receptor blocker, a prostaglandin and a carbonic anhydrase inhibitor; and a method for the prophylaxis or treatment of glaucoma by administering the composition to a patient.Type: ApplicationFiled: May 16, 2002Publication date: February 27, 2003Applicant: SANKYO COMPANY, LIMITEDInventor: Tomihisa Yokoyama
-
Publication number: 20020147211Abstract: An intraocular tension lowering composition for topical administration comprises an effective amount of an (i) angiotensin II antagonist, (ii) a boric aid and (iii) an ethylenediamine tetraacetic acid. Said composition has excellent intraocular tension lowering activity. Said composition may be effectively administered to humans and other warm-blooded animals to lower intraocular tension.Type: ApplicationFiled: December 10, 2001Publication date: October 10, 2002Applicant: SANKYO COMPANY, LIMITEDInventors: Tomihisa Yokoyama, Takashi Shiokari
-
Patent number: 6313164Abstract: Compounds of the formula (I): wherein one of m and n is 0, and the other is 0, 1 or 2; k is 0 or 1 to 12; R1 is hydrogen, a substituent which is an aryl or a heterocyclic, or an optionally substituted alkyl group; A is a single bond, an oxygen atom, a carbonyl group or a group of the formula —N(R2)CO—, —N(R2)CS—, —N(R2)SO2—, —CON(R2)N(R3)CO—, —CON(R2)CO—, —CON(R2)CS—, —CON(R2)SO2—, —O—CO—, —ON(R2)CO—, —ON(R2)SO2—, —O—CON(R2)N(R3)CO—, —O—CON(R2)CO—, —O—CON(R2)SO2—, —CO—O—, —CO—CO—, —CO—CON(R2)N(R3)CO—, —CO—CON(R2)CO—, —CO—CON(R2)SO2—, —N(R2)O—, —N(R2)COCO—, —N(R2)N(R3)CO—, —N(R2)N(R3)SO2—, —N(R2)CON(R3)N(R4)CO—, —N(R2)CON(R3)CO—, —N(R2)CON(R3)SO2&mdasType: GrantFiled: July 15, 1999Date of Patent: November 6, 2001Assignee: Sankyo Company, LimitedInventors: Takashi Fujita, Tomihisa Yokoyama
-
Patent number: 6013663Abstract: A compound of formula (I): ##STR1## wherein one of m and n represents 0, and the other represents 0, 1 or 2; k represents 0 or 1 to 12; R.sup.1 is hydrogen, an aryl, a heterocyclic, an alkyl, a hydroxy or --OR.sup.7, wherein R.sup.7 is an alkyl, an alkenyl or an aralkyl; A is --CON(R.sup.2)SO.sub.2--, wherein R.sup.2 is hydrogen, an alkyl or an aralkyl; B is a single bond; and pharmaceutically acceptable salts thereof. The compounds have the ability to enhance the activity of glutathione reductase and can therefore be used for the treatment and prevention of a variety of diseases including cataracts.Type: GrantFiled: March 31, 1998Date of Patent: January 11, 2000Assignee: Sankyo Company, LimitedInventors: Takashi Fujita, Tomihisa Yokoyama
-
Patent number: 5925664Abstract: A method of treating ocular hypertension and/or glaucoma in a mammal by locally administering to the eyes of a mammal a composition comprising an effective amount of a compound of the formula wherein R.sup.1 is lower alkyl, lower alkenyl, or R.sup.5 --A--B--, where R.sup.5 is hydrogen, lower alkyl, cycloalkyl or aliphatic acyl; A is oxygen or sulfur; and B is a single bond or a lower alkylene; R.sup.2 is lower alkyl, lower alkenyl, or --C(R.sup.6)(R.sup.7)(R.sup.8), wherein R.sup.6 is hydroxyl or lower alkoxy; and R.sup.7 and R.sup.8 each is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aryl or aralkyl; R.sup.3 is carboxyl or --CON(R.sup.9)(R.sup.10), wherein R.sup.9 and R.sup.10 each is hydrogen or lower alkyl; R.sup.4 is carboxyl, carboxycarbonyl or tetrazol-5-yl; or a pharmacologically acceptable salt or ester thereof.Type: GrantFiled: September 16, 1996Date of Patent: July 20, 1999Assignee: Sankyo Company, LimitedInventors: Tomihisa Yokoyama, Tsunemichi Hosokawa, Hiroaki Yanagisawa
-
Patent number: 5273976Abstract: Pharmaceutical compositions and methods for treatment of eye disorders employ ocular hypotensive compounds of the formula (I) ##STR1## wherein R.sup.1 is selected from hydrogen, C.sub.1 -C.sub.6 alkyl, and C.sub.1 -C.sub.6 alkoxy; each R.sup.2 is selected from hydrogen, C.sub.1 -C.sub.6 alkyl, halogen, nitro or carboxy; R.sup.3 is selected from amino, mono-substituted amino, and di-substituted amino; A and B each represents C.sub.1 -C.sub.6 alkylene, X represents --NH-- or --CH.sub.2 -- and n is 1, 2 or 3; and pharmaceutically acceptable salts or esters thereof.Type: GrantFiled: October 22, 1992Date of Patent: December 28, 1993Assignee: Sankyo Company, LimitedInventors: Tomihisa Yokoyama, Masaharu Fukami, Mitsuru Kataoka
-
Patent number: 5175161Abstract: Pharmaceutical compositions and methods for treatment of eye disorders employ ocular hypotensive compounds of the formula (I); ##STR1## (wherein: R.sup.1 is selected from hydrogen, C.sub.1 -C.sub.6 alkyl, and C.sub.1 -C.sub.6 alkoxy;each R.sup.2 is selected from hydrogen, C.sub.1 -C.sub.6 alkyl, halogen, nitro or carboxy;R.sup.3 is selected from heterocyclic, amino, mono-substituted amino, and di-substituted amino,A and B each represents C.sub.1 -C.sub.6 alkylene,X represents --NH-- or --CH.sub.2 --; and n is 1, 2 or 3)or pharmaceutically acceptable salts or esters thereof.Type: GrantFiled: April 3, 1990Date of Patent: December 29, 1992Assignee: Sankyo Company, LimitedInventors: Tomihisa Yokoyama, Masaharu Fukami, Mitsuru Kataoka